By leveraging our advanced technology platform, Creative Biolabs has developed one-stop HER2 assay portfolio services to meet your research needs.
The HER2 (also known as ERBB2) gene located on the long arm of chromosome 17, is a member of the type 1 tyrosine kinase growth factor receptor family, which are composed of epidermal growth factor receptor (EGFR)/ HER1, HER2, HER3, and HER4, and plays important roles in cell growth, survival differentiation and migration.
Usually, the HER2 extracellular domain forms homo or heterodimers to regulate the downstream signaling pathways. The formation of these dimers causes phosphorylation of tyrosine kinase residues in the cytoplasmic domain which could activate the PI3K and MAPK signaling pathways, leading to cell differentiation and proliferation.
HER2 is considered as an oncoprotein and over-expressed in 25-30% of breast cancers. HER2 is an established therapeutic target for breast cancer; and various agents have been approved for the treatment of HER2-positive breast cancer, such as trastuzumab, pertuzumab, lapatinib and trastuzumab emtansine (T-DM1). What’s more, HER2 overexpression or mutations have been presented in a wide range of tumor types, including colorectal, biliary tract, non-small-cell lung and bladder cancers. Therefore, the potential of novel HER2-targeted agents has been outstanding in clinical development.
Fig.1 Agents targeting HER2. (Oh, 2020)
To provide straightforward, end-to-end HER2 assay services, our team of highly trained technicians will help you work out the best service for you, and manage the whole process from sample handling to final report delivery within several days.
For further details, please don't hesitate to contact us and see how we can help you achieve your research goal.
Reference
For Research Use Only | Not For Clinical Use
Download our brochure